Leaps by Bayer

Indapta Therapeutics is a privately held biotechnology company that focuses on the development of a natural killer (NK) cell therapy platform aimed at treating various blood and solid tumor cancers. The company specializes in commercializing a proprietary, off-the-shelf, non-engineered, and allogeneic G-NK cell designed to enhance the immune response and significantly improve the cytotoxicity of antibody therapies. By harnessing the potent antibody-dependent cellular cytotoxicity (ADCC) activity of these NK cells, Indapta Therapeutics enables healthcare providers to offer innovative treatment options for patients battling cancer.

One.bio is an emerging biotechnology company spun out from UC Davis, specializing in the development of naturally-derived oligosaccharides for food, agriculture, and biopharmaceutical applications. Utilizing proprietary technology, the company creates novel oligosaccharides from natural products aimed at positively influencing the microbiome and enhancing immune function. One.bio's innovative ingredients provide clients with access to prebiotics and therapies that support both human and animal health, positioning the company as a significant player in the fields of nutrition and longevity.

Nuvig Therapeutics focuses on developing innovative therapies aimed at restoring immune homeostasis and rebalancing immune function. The company is dedicated to creating a pipeline of novel immune therapeutics specifically targeting chronic inflammatory and autoimmune diseases. By harnessing natural mechanisms to modulate immune responses, Nuvig seeks to enhance treatment options for patients, ultimately improving their health outcomes.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, a targeted cancer therapy using gene-engineered allogeneic CAR-NK cells designed to eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A for treating hepatocellular carcinoma.

Pairwise Plants is an innovative agricultural company based in San Diego, California, focused on gene editing to enhance the quality of fruits and vegetables. Founded in 2017 by a team of experts in biotechnology and agriculture, Pairwise utilizes advanced techniques, including base editing and high-fidelity enzymes, which are licensed from renowned institutions such as Harvard and Massachusetts General Hospital. The company develops new varieties of crops, including leafy greens, berries, and stone fruits, in addition to working with traditional crops like corn, soybeans, wheat, cotton, and canola. By collaborating with food and agriculture organizations, Pairwise aims to create healthier and more sustainable produce, with initial products expected to be available in the coming years.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

GRO Biosciences is a biotechnology company focused on developing advanced protein therapeutics to address various health conditions, including diabetes, growth disorders, and autoimmunity. The company employs innovative technologies in computational protein design and synthetic biology, which enable it to create genomically recoded strains of bacteria capable of incorporating non-standard amino acids into proteins. This approach enhances the properties of the proteins, resulting in increased potency, stability, and targeted delivery. Through its technology platform, GRO Biosciences aims to provide improved treatment options across multiple disease classes, contributing to advancements in medical therapeutics.

Huma is a global health technology company that specializes in creating a modular platform for digital 'hospitals at home' across various disease areas. The platform integrates predictive algorithms, digital biomarkers, and real-world data to enhance proactive and predictive healthcare. By connecting information from hospital databases, patient wearables, and mobile devices, Huma provides healthcare providers with real-time insights. The company focuses on advancing connected care for patients and accelerating research and therapy development. It collaborates with leading healthcare institutions to assess and improve health outcomes, empowering healthcare professionals to utilize data effectively for better patient care.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Summer Health is a provider of pediatric telehealth services designed to simplify access to healthcare for families. The company enables timely communication with board-certified pediatricians through a text-based platform, allowing users to receive expert answers and reliable advice quickly. Summer Health's services include health tracking and personalized healthcare plans, ensuring that patients can obtain necessary care within minutes. By leveraging digital technology, Summer Health aims to enhance the healthcare experience for families navigating health concerns.

Capstan Therapeutics is a biotechnology company focused on advancing precision in vivo cell engineering to create therapeutics for various disease categories that have unmet or underserved clinical needs. The company specializes in expanding the therapeutic potential of RNA-based therapies through proprietary targeted delivery systems. Their platform utilizes targeted lipid nanoparticles to enhance off-the-shelf immunotherapies, providing tight control over dosage and activity of engineered cells. This approach aims to develop transformative products for conditions such as oncology, fibrosis, and inflammation-related diseases.

9amHealth is a healthcare service provider that aims to deliver comprehensive medical support for chronic conditions such as diabetes, hypertension, and hyperlipidemia. The company offers personalized care plans, prescription medication, at-home lab tests, and unlimited virtual visits, ensuring that patients have direct access to affordable and compassionate care. By redesigning all care elements into a single digital service, 9amHealth caters to the modern realities of patients' lives, making healthcare always available and convenient, even for those without insurance. Its focus on chronic conditions highlights its commitment to improving the health and well-being of customers in the United States.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Sudo Biosciences is a biopharmaceutical company focused on designing and developing innovative medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain. This domain plays a vital role in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. Sudo Biosciences has a pipeline of next-generation TYK2 inhibitors, including a candidate aimed at treating multiple sclerosis and neurodegenerative diseases characterized by neuroinflammation, as well as a topical treatment for immune-mediated dermatologic diseases. The company's mission is to provide effective therapies for patients at competitive costs, thereby transforming their lives and addressing unmet medical needs.

Jixing Pharmaceuticals is a global biotechnology company focused on developing and commercializing innovative therapeutics for cardiovascular and ophthalmic diseases. The company’s asset pipeline includes treatments for conditions such as hypertrophic cardiomyopathy, heart failure, presbyopia, hypertension, and dry eye disease. Jixing Pharmaceuticals has in-licensed a small molecule cardiac myosin inhibitor, designed to address the specific needs of patients suffering from hypertrophic cardiomyopathy. By providing advanced treatment options, the company aims to meet the significant unmet medical needs of patients in China and beyond, particularly those facing serious, life-threatening health challenges in the fields of cardiology and ophthalmology.

NewLeaf Symbiotics, Inc. is an agriculture technology company based in Saint Louis, Missouri, dedicated to the research, development, and commercialization of beneficial symbiotic bacteria aimed at enhancing plant health and increasing crop yields. The company focuses on naturally occurring bacteria, particularly pink pigmented facultative methylotrophs, which are utilized across various agricultural sectors, including row crops, vegetables, fruits, and ornamental plants. NewLeaf Symbiotics conducts extensive laboratory, greenhouse, and field trials to validate the effectiveness of its products, providing farmers with sustainable solutions to combat plant diseases and improve agricultural productivity. Originally founded as TrophoMax, LLC in 2011, the company rebranded in July 2012 to better reflect its mission and objectives in the agricultural biotechnology space.

65LAB is a biotechnology company that specializes in accelerating the development of innovative therapies. It operates an accelerator program designed to commercialize promising therapeutic projects. The company identifies potential therapies from applicants, provides funding and mentoring, and helps these projects achieve preclinical proof-of-concept.

Rantizo, Inc. is an Iowa-based company that specializes in the development and sale of agricultural drones and related equipment. Founded in 2018, Rantizo offers a range of products including trailers, drone sprayers, spreaders, battery chargers, and batteries. The company employs advanced electrostatic spraying technology, which allows for even distribution of pesticides and chemicals across crops, addressing challenges related to uneven coverage. In addition to its product offerings, Rantizo also provides spraying services, enabling farmers to efficiently apply treatments precisely when and where they are needed in the field. By integrating its software with drone manufacturers and agronomy systems, Rantizo enhances the operational efficiency of large-scale agriculture, making the application process more profitable and streamlined for farmers.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Guardian Agriculture is a developer of autonomous electric vertical takeoff and landing (eVTOL) systems specifically designed for precision agricultural applications. The company offers a sustainable solution for crop protection, enabling farmers to harness aerial application technology while reducing their environmental footprint and minimizing product resistance. Its integrated system operates safely over farmland, capturing valuable application data that helps refine chemical usage and enhance crop sustainability. By providing crop protection as a service and precision agriculture solutions, Guardian Agriculture empowers growers to optimize their farming practices and extend their operational reach.

ChrysaLabs is a Montreal-based company established in 2017 that specializes in developing innovative technology for soil analysis. The company has created a portable probe that allows for real-time measurement of soil nutrients and health, providing valuable insights for producers and agronomists. This advanced optical technology can assess soil properties at various depths without the need for sample preparation, enabling users to directly evaluate available nutrients in the field. In addition, ChrysaLabs offers a management platform that facilitates data access and enables informed decision-making to enhance fertilizer management and optimize crop yields.

Andes Ag, Inc., founded in 2018 and headquartered in San Francisco, California, specializes in developing microbe-based seed technologies aimed at promoting sustainable agriculture. The company leverages beneficial microbes that have naturally co-evolved with plants over millennia. Through scientific research and advanced predictive software powered by artificial intelligence, Andes creates customized microbe-based formulations designed to enhance crop yields, accelerate growth, and enable cultivation in traditionally unsuitable lands. These solutions also aim to reduce the reliance on fertilizers and pesticides, helping farmers address the challenges posed by global climate change. Andes is positioned to contribute significantly to a new green revolution, fostering responsible and environmentally friendly agricultural practices.

Fork & Good is a Brooklyn-based food company founded in 2018 that specializes in developing a new approach to food production. The company focuses on producing cultivated meat, which involves growing real meat cells to create pure animal proteins and fats that are clean, traceable, and flavorful. By emphasizing sustainability, Fork & Good aims to provide consumers with affordable and healthy food options, ensuring that its products deliver the essential nutrients while addressing the growing demand for sustainable food solutions.

Paratus Sciences is a biotechnology company focused on enhancing human health and health security through the study of bat biology. By investigating the unique characteristics of the bat genome, the company aims to identify and develop therapeutics for various diseases. Leveraging insights gained from bat biology, Paratus Sciences seeks to enable patients to combat and potentially cure the diseases they face. Through its innovative approach, the company aspires to contribute significantly to advancements in medical treatments and public health.

EarthOptics is a company focused on sustainable agricultural management through the development of a global soil cloud platform. Utilizing advanced sensors and machine learning, EarthOptics creates highly accurate soil maps by analyzing far fewer soil samples. The platform provides detailed insights into various soil attributes, including compaction, fertility, and carbon levels. This technology empowers farmers, ranchers, and land managers to make informed decisions that enhance profitability and sustainability in soil management. Additionally, EarthOptics offers near-real-time actionable data that aids in monitoring soil health, benefiting both agricultural practices and carbon credit verification efforts.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.

Sound Agriculture Company develops innovative crop protection and enhancement products aimed at improving agricultural yields and increasing farm revenues. Based in Emeryville, California, the company focuses on leveraging molecular discovery and life sciences to create climate-resilient crops that enhance harvest yields while promoting sustainable farming practices. Its flagship product, Source, enhances in-season nutrient uptake by unlocking existing nitrogen and phosphorus in the soil, thereby maximizing crop performance. Additionally, Sound Agriculture produces solutions that support improved photosynthesis, water efficiency, and overall crop health, contributing to more sustainable and nutritious food production. The company, originally known as Asilomar Bio, Inc., was founded in 2012 and rebranded in 2018, reflecting its commitment to addressing critical agricultural challenges.

NuCicer is a company dedicated to transforming chickpeas into a staple superfood through the development of innovative varieties that offer enhanced nutritional benefits, improved flavor, and cost-effective ingredients. By leveraging the world's most diverse chickpea breeding library alongside a proprietary breeding innovation platform, NuCicer integrates plant genetics and machine learning to create customized chickpea varieties. These varieties are designed to have higher protein content and specific functional and nutritional properties, while also addressing environmental sustainability concerns. This approach not only meets the growing demand for nutritious food options but also supports the alternative-meat sector, ultimately aiming to reduce agriculture's environmental footprint and provide diverse solutions for the agri-food system.

Capstan Therapeutics is a biotechnology company focused on advancing precision in vivo cell engineering to create therapeutics for various disease categories that have unmet or underserved clinical needs. The company specializes in expanding the therapeutic potential of RNA-based therapies through proprietary targeted delivery systems. Their platform utilizes targeted lipid nanoparticles to enhance off-the-shelf immunotherapies, providing tight control over dosage and activity of engineered cells. This approach aims to develop transformative products for conditions such as oncology, fibrosis, and inflammation-related diseases.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, a targeted cancer therapy using gene-engineered allogeneic CAR-NK cells designed to eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A for treating hepatocellular carcinoma.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, a targeted cancer therapy using gene-engineered allogeneic CAR-NK cells designed to eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A for treating hepatocellular carcinoma.

9amHealth is a healthcare service provider that aims to deliver comprehensive medical support for chronic conditions such as diabetes, hypertension, and hyperlipidemia. The company offers personalized care plans, prescription medication, at-home lab tests, and unlimited virtual visits, ensuring that patients have direct access to affordable and compassionate care. By redesigning all care elements into a single digital service, 9amHealth caters to the modern realities of patients' lives, making healthcare always available and convenient, even for those without insurance. Its focus on chronic conditions highlights its commitment to improving the health and well-being of customers in the United States.

Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-cell therapies designed to eradicate tumors.

Apollo Agriculture, established in 2015, is a Kenyan agtech company with a presence in Nairobi. It specializes in providing smallholder farmers with access to critical farming inputs, financing, and advisory services. The company leverages agronomic machine learning, remote sensing, and mobile technology to assess credit risk and tailor financial and technical assistance to each farmer's unique needs and location. This approach aims to enhance farm yields and profitability in emerging markets, with a focus on Kenya.

Triumvira Immunologics USA, Inc. is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies aimed at improving cancer treatment outcomes. Its primary offerings include chimeric antigen receptor (CAR) therapies and engineered T cell receptor (TCR) therapies. A key aspect of Triumvira's approach is its proprietary T cell Antigen Coupler (TAC) technology, which recruits the entire natural T cell receptor and operates independently of the major histocompatibility complex (MHC). This technology enables the development of more effective therapies for a wider array of patients suffering from both solid and liquid malignancies, as well as other diseases beyond cancer.

Woebot Health is a digital mental healthcare provider that offers a platform designed to deliver personalized support and guidance. Utilizing advanced artificial intelligence and natural language processing, Woebot Health incorporates clinically proven therapeutic techniques into its services. The centerpiece of its offering is Woebot, an engaging relational agent that facilitates continuous, empathic, and user-friendly interactions. This innovative approach allows individuals and organizations to access effective mental health support seamlessly, fitting into daily life and providing help whenever needed. Woebot Health aims to enhance mental well-being through scalable digital tools, making mental health resources more accessible to a broad audience.

Vivante Health, Inc. is a digital health company focused on addressing digestive health and chronic conditions. Founded in 2016, it has developed GIThrive, a technology platform designed to provide actionable insights for managing digestive issues. GIThrive offers a comprehensive digital gut health program that includes expert guidance, 24/7 support, and personalized care plans. The company also provides GIMate, an innovative portable breathalyzer that identifies trigger foods, and GutCheck, which analyzes gut bacteria to recommend tailored diets. Vivante Health emphasizes individualized care, utilizing a scalable platform that integrates real-time data from biometric devices and partners. This approach not only aims to reduce healthcare costs and improve employee health for large employers and health plans but also enhances user empowerment through advanced science and technology. Headquartered in Houston, Texas, with an additional office in Athens, Greece, Vivante Health continues to prioritize innovative solutions in the realm of digestive health.

Indapta Therapeutics is a privately held biotechnology company that focuses on the development of a natural killer (NK) cell therapy platform aimed at treating various blood and solid tumor cancers. The company specializes in commercializing a proprietary, off-the-shelf, non-engineered, and allogeneic G-NK cell designed to enhance the immune response and significantly improve the cytotoxicity of antibody therapies. By harnessing the potent antibody-dependent cellular cytotoxicity (ADCC) activity of these NK cells, Indapta Therapeutics enables healthcare providers to offer innovative treatment options for patients battling cancer.

Dewpoint Therapeutics, Inc. is a Boston-based biotech company focused on the research and development of biomolecular condensates, aiming to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunological conditions, cardiovascular issues, women's health, and viral infections. Founded in 2018, the company utilizes a proprietary platform that combines experimental techniques with machine-learning-based image analysis to visualize and study biomolecular condensates. This technology includes a collection of genetically engineered cell lines designed to track condensates and mitigate harmful protein sequestration. By leveraging its advanced capabilities, Dewpoint Therapeutics seeks to address unmet medical needs and enhance drug discovery across multiple therapeutic areas, collaborating with leading academic and pharmaceutical partners to further its mission.

Gandeeva Therapeutics is a precision biotechnology company focused on developing innovative therapeutics by leveraging cryogenic electron microscopy and machine learning to target and modulate key protein-protein interactions. The company employs a comprehensive structure-guided drug discovery platform that includes target prediction and validation, hit identification from virtual and fragment libraries, and lead optimization. Gandeeva's preclinical oncology pipeline is designed to address challenging cancers through the creation of novel protein interaction modulators, specifically interfacial glues and allosteric inhibitors. Headquartered in the Greater Vancouver area, Canada, Gandeeva Therapeutics aims to enhance treatment options and reduce the risks of late-stage clinical failures in oncology.

Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.

Cellino is focused on developing a scalable, automated biomanufacturing system aimed at producing personalized cell therapies. The company's innovative platform leverages AI-guided laser editing to generate autologous induced pluripotent stem cells (iPSCs) efficiently and at scale. By utilizing image-guided machine learning, single-cell laser processing, and robotics, Cellino seeks to make advanced, potentially curative treatments accessible for a range of chronic degenerative diseases, including vision loss and Parkinson's disease. The company's mission is to transform healthcare by enabling personalized therapies that can significantly improve patient outcomes and overall health.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Bloom Science, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, that specializes in developing neuroprotective therapies leveraging the microbiome to treat epilepsy and other neurological disorders. Founded in 2017, the company employs its proprietary IrisRx™ platform to explore innovative treatments that target the Gut-Brain Axis, aiming to create therapeutics with enhanced safety profiles. Bloom Science's approach focuses on harnessing gut commensal microbes and integrating insights from synthetic biology to develop multi-functional therapeutics. The company is advancing a robust pipeline of programs addressing complex conditions such as Dravet syndrome, various rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders, with the goal of delivering transformative solutions for patients facing serious, life-altering illnesses.

MedArrive, Inc. is a New York-based company that operates a software-as-a-service health platform designed to enhance care management by connecting healthcare providers with patients in their homes. The platform integrates clinical data into electronic medical records and facilitates communication and billing processes. By utilizing emergency medical services professionals, MedArrive enables healthcare providers to deliver high-quality care at home, improving access for vulnerable populations while reducing overall healthcare costs. This innovative approach fosters patient self-advocacy and continuity of care, helping to re-engage patients in primary care and enhance health outcomes. MedArrive's technology and holistic care model represent a strategic effort to bridge the gap between virtual care and in-person support, ultimately benefiting both patients and healthcare providers.

GRO Biosciences is a biotechnology company focused on developing advanced protein therapeutics to address various health conditions, including diabetes, growth disorders, and autoimmunity. The company employs innovative technologies in computational protein design and synthetic biology, which enable it to create genomically recoded strains of bacteria capable of incorporating non-standard amino acids into proteins. This approach enhances the properties of the proteins, resulting in increased potency, stability, and targeted delivery. Through its technology platform, GRO Biosciences aims to provide improved treatment options across multiple disease classes, contributing to advancements in medical therapeutics.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Mozart Therapeutics is a biotechnology startup dedicated to developing innovative therapies for autoimmune and inflammatory diseases. The company specializes in creating disease-modifying CD8 T cell modulators, leveraging a unique regulatory CD8 T cell network to target a specific subset of T lymphocytes. These modulators aim to restore immune balance and mitigate the damage caused by autoreactive and pathogenic immune responses. By focusing on first-in-class CD8 Treg modulators, Mozart Therapeutics seeks to delay the onset and improve the management of various autoimmune disorders, thereby providing healthcare professionals with advanced treatment options for their patients.

Zerigo Health, formerly known as Clarify Medical, Inc., specializes in home therapy solutions for chronic skin conditions such as psoriasis, eczema, and vitiligo. The company offers innovative products like the Clarify mobile ultra violet B treatment system and the Home Light Therapy System, both designed to facilitate phototherapy in a home setting. Zerigo Health aims to enhance the ease and effectiveness of UVB therapy through a connected system that allows patients to manage their treatment via a smartphone app. This app enables users to control dosing, frequency, and duration of therapy, ensuring adherence to guidelines set by dermatology experts. By allowing patients to administer their treatments with clinical precision, Zerigo Health improves the overall patient experience, while also monitoring compliance and progress, ultimately empowering individuals to manage their chronic skin conditions more effectively from the comfort of their homes.

EarthOptics is a company focused on sustainable agricultural management through the development of a global soil cloud platform. Utilizing advanced sensors and machine learning, EarthOptics creates highly accurate soil maps by analyzing far fewer soil samples. The platform provides detailed insights into various soil attributes, including compaction, fertility, and carbon levels. This technology empowers farmers, ranchers, and land managers to make informed decisions that enhance profitability and sustainability in soil management. Additionally, EarthOptics offers near-real-time actionable data that aids in monitoring soil health, benefiting both agricultural practices and carbon credit verification efforts.

Sound Agriculture Company develops innovative crop protection and enhancement products aimed at improving agricultural yields and increasing farm revenues. Based in Emeryville, California, the company focuses on leveraging molecular discovery and life sciences to create climate-resilient crops that enhance harvest yields while promoting sustainable farming practices. Its flagship product, Source, enhances in-season nutrient uptake by unlocking existing nitrogen and phosphorus in the soil, thereby maximizing crop performance. Additionally, Sound Agriculture produces solutions that support improved photosynthesis, water efficiency, and overall crop health, contributing to more sustainable and nutritious food production. The company, originally known as Asilomar Bio, Inc., was founded in 2012 and rebranded in 2018, reflecting its commitment to addressing critical agricultural challenges.

Andes Ag, Inc., founded in 2018 and headquartered in San Francisco, California, specializes in developing microbe-based seed technologies aimed at promoting sustainable agriculture. The company leverages beneficial microbes that have naturally co-evolved with plants over millennia. Through scientific research and advanced predictive software powered by artificial intelligence, Andes creates customized microbe-based formulations designed to enhance crop yields, accelerate growth, and enable cultivation in traditionally unsuitable lands. These solutions also aim to reduce the reliance on fertilizers and pesticides, helping farmers address the challenges posed by global climate change. Andes is positioned to contribute significantly to a new green revolution, fostering responsible and environmentally friendly agricultural practices.

Woebot Health is a digital mental healthcare provider that offers a platform designed to deliver personalized support and guidance. Utilizing advanced artificial intelligence and natural language processing, Woebot Health incorporates clinically proven therapeutic techniques into its services. The centerpiece of its offering is Woebot, an engaging relational agent that facilitates continuous, empathic, and user-friendly interactions. This innovative approach allows individuals and organizations to access effective mental health support seamlessly, fitting into daily life and providing help whenever needed. Woebot Health aims to enhance mental well-being through scalable digital tools, making mental health resources more accessible to a broad audience.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Kojin Therapeutics, founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, focuses on advancing a drug discovery platform that links complex cell states to established biochemical processes, specifically ferroptosis, which involves iron-dependent cell death. This innovative approach enables the development of targeted therapies for a wide range of challenging diseases that are often difficult to treat. The company's biology platform aims to identify disease-specific targets, ensuring that patients receive effective treatments tailored to their specific conditions. Kojin Therapeutics is supported by a diverse group of investors, including Polaris Partners, Newpath Partners, and AbbVie, among others.

Ada Health is a global health company established in 2011 and headquartered in Berlin, Germany. Founded by a team of doctors, scientists, and industry pioneers, Ada Health aims to enhance personal health management through its innovative platform that integrates medical knowledge with intelligent technology. The platform empowers users by providing personalized assessments of their symptoms based on targeted questions about their health. Additionally, it facilitates online video consultations, disease monitoring, and prevention strategies, allowing healthcare professionals to maintain a comprehensive overview of their patients' health situations. Ada Health collaborates with prominent health systems and global non-profit organizations to realize its vision of improving health outcomes for individuals and enhancing the effectiveness of medical care.

Huma is a global health technology company that specializes in creating a modular platform for digital 'hospitals at home' across various disease areas. The platform integrates predictive algorithms, digital biomarkers, and real-world data to enhance proactive and predictive healthcare. By connecting information from hospital databases, patient wearables, and mobile devices, Huma provides healthcare providers with real-time insights. The company focuses on advancing connected care for patients and accelerating research and therapy development. It collaborates with leading healthcare institutions to assess and improve health outcomes, empowering healthcare professionals to utilize data effectively for better patient care.

Edifice Health is a company that emerged from a decade-long research initiative at Stanford University, specifically the Stanford 1,000 Immunomes Project. It has developed an innovative biomarker composite scoring system designed to assess immune health and determine an individual's Inflammatory Age®, which can predict the onset of various chronic diseases. This technology enables comprehensive health insights that guide individuals in altering their aging trajectory. Edifice Health's approach focuses on advancing testing methods for systemic chronic inflammation and enhancing immune health. The company's applications extend to personalized nutritional and immunological sciences, utilizing AI-driven technology to tackle chronic diseases globally. This empowers healthcare professionals to detect systemic chronic inflammation early, thereby promoting better immune health and facilitating healthier aging.

Guardian Agriculture is a developer of autonomous electric vertical takeoff and landing (eVTOL) systems specifically designed for precision agricultural applications. The company offers a sustainable solution for crop protection, enabling farmers to harness aerial application technology while reducing their environmental footprint and minimizing product resistance. Its integrated system operates safely over farmland, capturing valuable application data that helps refine chemical usage and enhance crop sustainability. By providing crop protection as a service and precision agriculture solutions, Guardian Agriculture empowers growers to optimize their farming practices and extend their operational reach.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

CoverCress Inc. is a biotechnology company based in Saint Louis, Missouri, founded in 2013. The company focuses on developing and commercializing field pennycress as an oilseed crop, which is utilized for producing oil for renewable fuels and meal for livestock feed. By genetically improving pennycress, CoverCress aims to create a sustainable cover crop that enhances soil health and offers benefits for farmers during corn and soybean planting seasons. The company’s efforts are centered on sustainable agricultural practices, allowing farmers to maximize yields while minimizing input and carbon emissions. Formerly known as Arvegenix Inc., CoverCress reflects a commitment to innovation in agriculture, biotechnology, and renewable energy solutions.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Grão Direto LTDA is a Brazilian company that operates a digital trading platform designed for the buying and selling of grains. Founded in 2016 and based in Uberaba, the platform connects farmers and grain buyers, facilitating efficient interactions for various trading types, including spot, future, and barter trades. Grão Direto enhances market intelligence, enabling users to make informed decisions regarding market rates and grain choices. The platform also supports ancillary processes related to grain trading, such as logistics, contract management, and financial products. By providing a web platform and a mobile application, Grão Direto aims to streamline the agricultural commodity chain, serving diverse stakeholders like cooperatives, traders, and brokers while promoting more agile and effective market operations.

Amfora, Inc. is a biotechnology company based in San Francisco, California, founded in 2016. The company focuses on developing nutritional forage crops through innovative biotechnological processes, particularly gene editing, to enhance the protein density of various crops, including soybeans, wheat, and rice. Amfora aims to address the growing global demand for high-protein foods by increasing the nutritional density of food and feed crops. By doing so, the company aspires to contribute to sustainable agricultural practices while simultaneously reducing food costs and the environmental impact associated with food production. Amfora's mission highlights its commitment to improving wellness and nutrition as part of the broader plant-based protein revolution.

Pairwise Plants is an innovative agricultural company based in San Diego, California, focused on gene editing to enhance the quality of fruits and vegetables. Founded in 2017 by a team of experts in biotechnology and agriculture, Pairwise utilizes advanced techniques, including base editing and high-fidelity enzymes, which are licensed from renowned institutions such as Harvard and Massachusetts General Hospital. The company develops new varieties of crops, including leafy greens, berries, and stone fruits, in addition to working with traditional crops like corn, soybeans, wheat, cotton, and canola. By collaborating with food and agriculture organizations, Pairwise aims to create healthier and more sustainable produce, with initial products expected to be available in the coming years.

Ukko is a biotechnology company focused on enhancing the quality of life for individuals affected by food allergies and disorders. The company utilizes a computational engineering platform that employs artificial intelligence, immunology, and protein engineering to redesign food allergens into therapeutics that are both safe and effective. By creating a comprehensive, clinically validated map of the molecular structures associated with food allergies, Ukko reveals critical insights into the biological mechanisms governing human-food interactions. This innovative approach enables the development of new protein versions that do not provoke an immune response, providing a novel strategy for treating protein-based allergies.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, a targeted cancer therapy using gene-engineered allogeneic CAR-NK cells designed to eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A for treating hepatocellular carcinoma.

Rantizo, Inc. is an Iowa-based company that specializes in the development and sale of agricultural drones and related equipment. Founded in 2018, Rantizo offers a range of products including trailers, drone sprayers, spreaders, battery chargers, and batteries. The company employs advanced electrostatic spraying technology, which allows for even distribution of pesticides and chemicals across crops, addressing challenges related to uneven coverage. In addition to its product offerings, Rantizo also provides spraying services, enabling farmers to efficiently apply treatments precisely when and where they are needed in the field. By integrating its software with drone manufacturers and agronomy systems, Rantizo enhances the operational efficiency of large-scale agriculture, making the application process more profitable and streamlined for farmers.

Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.

Azitra Inc. is a clinical-stage biopharmaceutical company based in Farmington, Connecticut, specializing in microbiome-based therapeutics for skin diseases. Founded in 2014, Azitra leverages extensive scientific research on the skin microbiome to develop innovative treatments for various adverse skin conditions. The company’s proprietary platform includes a microbial library of engineered bacterial strains, notably Staphylococcus epidermidis, which are screened for therapeutic properties. In collaboration with researchers from Yale University and the Jackson Laboratory, Azitra employs advanced technologies such as artificial intelligence and machine learning to analyze and predict the efficacy of its strains. The company focuses on precision dermatology by developing live biotherapeutic products and engineered proteins for topical application, aiming to address unmet medical needs in the dermatological field.

Dewpoint Therapeutics, Inc. is a Boston-based biotech company focused on the research and development of biomolecular condensates, aiming to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunological conditions, cardiovascular issues, women's health, and viral infections. Founded in 2018, the company utilizes a proprietary platform that combines experimental techniques with machine-learning-based image analysis to visualize and study biomolecular condensates. This technology includes a collection of genetically engineered cell lines designed to track condensates and mitigate harmful protein sequestration. By leveraging its advanced capabilities, Dewpoint Therapeutics seeks to address unmet medical needs and enhance drug discovery across multiple therapeutic areas, collaborating with leading academic and pharmaceutical partners to further its mission.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Salt Lake City, Utah, that focuses on revolutionizing drug discovery through the integration of advanced technologies such as artificial intelligence, automation, and bioinformatics. Founded in 2013, the company has developed a comprehensive drug discovery platform that includes various tools and software, such as ReChem for chemical compound design, ReScreen for managing complex experimental workflows, and RePredict for modeling drug relationships using machine learning. These innovations enable Recursion to generate extensive biological and chemical datasets, facilitating the exploration of foundational biology and accelerating the development of new therapeutic solutions. Through its unique approach, Recursion aims to significantly enhance patient outcomes and streamline the drug discovery process.

Triumvira Immunologics USA, Inc. is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies aimed at improving cancer treatment outcomes. Its primary offerings include chimeric antigen receptor (CAR) therapies and engineered T cell receptor (TCR) therapies. A key aspect of Triumvira's approach is its proprietary T cell Antigen Coupler (TAC) technology, which recruits the entire natural T cell receptor and operates independently of the major histocompatibility complex (MHC). This technology enables the development of more effective therapies for a wider array of patients suffering from both solid and liquid malignancies, as well as other diseases beyond cancer.

Unfold Bio, Inc. specializes in developing seeds for indoor vertical farming, offering varieties such as lettuce, spinach, cucumbers, tomatoes, and peppers. Founded in 2020 and based in Sacramento, California, the company utilizes advanced seed genetics and agronomic expertise to enhance productivity and flavor, catering to the growing vertical farming market. Its innovative approach allows for optimal water use, minimizes reliance on synthetic inputs, and facilitates food production in environments with limited arable land. Unfold collaborates with vertical farming operators, technology providers, and stakeholders across the produce supply chain to foster a sustainable local food culture. The company also conducts research and development operations in California and Singapore, aiming to improve food variety and consumer experiences in the industry.

Vesigen Therapeutics, established in 2020 and based in Cambridge, Massachusetts, specializes in developing innovative therapeutic products. The company's core technology, ARMMs (ARRDC1 Mediated Microvesicles), facilitates the delivery of various payloads such as RNAs, proteins, and gene-editing complexes directly into the cytoplasm of target cells. This approach overcomes intracellular delivery barriers, expanding the scope of treatable conditions and enabling new therapies for unmet medical needs.

Apollo Agriculture, established in 2015, is a Kenyan agtech company with a presence in Nairobi. It specializes in providing smallholder farmers with access to critical farming inputs, financing, and advisory services. The company leverages agronomic machine learning, remote sensing, and mobile technology to assess credit risk and tailor financial and technical assistance to each farmer's unique needs and location. This approach aims to enhance farm yields and profitability in emerging markets, with a focus on Kenya.

CoverCress Inc. is a biotechnology company based in Saint Louis, Missouri, founded in 2013. The company focuses on developing and commercializing field pennycress as an oilseed crop, which is utilized for producing oil for renewable fuels and meal for livestock feed. By genetically improving pennycress, CoverCress aims to create a sustainable cover crop that enhances soil health and offers benefits for farmers during corn and soybean planting seasons. The company’s efforts are centered on sustainable agricultural practices, allowing farmers to maximize yields while minimizing input and carbon emissions. Formerly known as Arvegenix Inc., CoverCress reflects a commitment to innovation in agriculture, biotechnology, and renewable energy solutions.

Oerth Bio LLC is a biotechnology company focused on developing innovative solutions for crop protection. Established in 2019 and based in Durham, North Carolina, the company utilizes PROTAC (proteolysis targeting chimeras) technology to create targeted protein degraders specifically for agricultural applications. This approach aims to enhance crop yields while minimizing reliance on harmful pesticides, promoting sustainable agricultural practices. Oerth Bio's technology not only contributes to healthier crops but also aligns with the growing demand for environmentally friendly farming methods.

NewLeaf Symbiotics, Inc. is an agriculture technology company based in Saint Louis, Missouri, dedicated to the research, development, and commercialization of beneficial symbiotic bacteria aimed at enhancing plant health and increasing crop yields. The company focuses on naturally occurring bacteria, particularly pink pigmented facultative methylotrophs, which are utilized across various agricultural sectors, including row crops, vegetables, fruits, and ornamental plants. NewLeaf Symbiotics conducts extensive laboratory, greenhouse, and field trials to validate the effectiveness of its products, providing farmers with sustainable solutions to combat plant diseases and improve agricultural productivity. Originally founded as TrophoMax, LLC in 2011, the company rebranded in July 2012 to better reflect its mission and objectives in the agricultural biotechnology space.

Immunitas Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing targeted therapeutics for patients with complex cancers. Founded in 2019, the company utilizes a single-cell sequencing platform to analyze the biology of immune cells within human tumors. This innovative approach allows Immunitas to identify novel drug targets and develop key biomarkers that guide patient selection for their therapies. By emphasizing research rooted in human biology, Immunitas aims to bridge the gap between laboratory discoveries and clinical applications. The company is advancing multiple programs toward early human studies, leveraging its expertise in antibody discovery and engineering to create effective treatments that modulate identified targets.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Huma is a global health technology company that specializes in creating a modular platform for digital 'hospitals at home' across various disease areas. The platform integrates predictive algorithms, digital biomarkers, and real-world data to enhance proactive and predictive healthcare. By connecting information from hospital databases, patient wearables, and mobile devices, Huma provides healthcare providers with real-time insights. The company focuses on advancing connected care for patients and accelerating research and therapy development. It collaborates with leading healthcare institutions to assess and improve health outcomes, empowering healthcare professionals to utilize data effectively for better patient care.

BlueRock Therapeutics LP is a biotechnology company specializing in the development and manufacture of engineered cell therapies, focusing on neurology, cardiology, and immunology. Utilizing its CELL+GENE platform, the company aims to create induced pluripotent stem cell (iPSC) therapies to address a variety of diseases, with initial programs targeting heart muscle regeneration in patients who have experienced heart attacks or chronic heart failure. Founded in 2016 and headquartered in Cambridge, Massachusetts, BlueRock Therapeutics also maintains offices in New York and Toronto. The company provides stable master cell banks, including healthy donor cells and tools for immune evasion, facilitating the cultivation and expansion of these innovative therapies. As of late 2019, BlueRock Therapeutics operates as a subsidiary of Bayer Aktiengesellschaft.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Dewpoint Therapeutics, Inc. is a Boston-based biotech company focused on the research and development of biomolecular condensates, aiming to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunological conditions, cardiovascular issues, women's health, and viral infections. Founded in 2018, the company utilizes a proprietary platform that combines experimental techniques with machine-learning-based image analysis to visualize and study biomolecular condensates. This technology includes a collection of genetically engineered cell lines designed to track condensates and mitigate harmful protein sequestration. By leveraging its advanced capabilities, Dewpoint Therapeutics seeks to address unmet medical needs and enhance drug discovery across multiple therapeutic areas, collaborating with leading academic and pharmaceutical partners to further its mission.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on the agriculture industry through the development of biological products. Founded in 2012, AgBiome leverages its expertise in plant-associated microbes and modern genomics to create innovative solutions aimed at enhancing plant health, pest resistance, and crop yields. The company addresses critical agricultural challenges, including soil-borne diseases, insects, and nematodes, by offering fungicides and a platform that identifies and screens diverse microbial strains. AgBiome collaborates with prominent agricultural partners to accelerate discovery processes and broaden the reach of its sustainable products in global markets. With a dedicated team of over 85 employees and a state-of-the-art laboratory and greenhouse facility, AgBiome is committed to improving food production responsibly.

Resson is a bioinformatics and data analytics company based in Fredericton, New Brunswick, specializing in customized agriculture solutions for large corporate clients. The company employs advanced technologies such as cloud-based data processing, swarm robotics, computer vision, and machine learning to enhance agricultural productivity. Its proprietary platform, the Resson Agricultural Management and Analytics System, analyzes crop metrics to assess the health and status of crops. By providing actionable insights derived from field data, Resson enables agricultural operators to optimize their operations, improve efficiency, increase yields, and maximize profitability.

Pairwise Plants is an innovative agricultural company based in San Diego, California, focused on gene editing to enhance the quality of fruits and vegetables. Founded in 2017 by a team of experts in biotechnology and agriculture, Pairwise utilizes advanced techniques, including base editing and high-fidelity enzymes, which are licensed from renowned institutions such as Harvard and Massachusetts General Hospital. The company develops new varieties of crops, including leafy greens, berries, and stone fruits, in addition to working with traditional crops like corn, soybeans, wheat, cotton, and canola. By collaborating with food and agriculture organizations, Pairwise aims to create healthier and more sustainable produce, with initial products expected to be available in the coming years.

Joyn Bio LLC, established in 2017, is a Boston-based joint venture between Leaps by Bayer and Ginkgo Bioworks, Inc., with a plant research facility in West Sacramento, California. The company specializes in developing probiotics for plants using synthetic biology, aiming to provide cereal crops like corn, wheat, and rice with their nitrogen needs, thereby reducing agriculture's reliance on chemical fertilizers and mitigating environmental impacts. Joyn Bio's team comprises microbiologists, synthetic biologists, plant scientists, and ecologists working collaboratively to address these challenges.

NewLeaf Symbiotics, Inc. is an agriculture technology company based in Saint Louis, Missouri, dedicated to the research, development, and commercialization of beneficial symbiotic bacteria aimed at enhancing plant health and increasing crop yields. The company focuses on naturally occurring bacteria, particularly pink pigmented facultative methylotrophs, which are utilized across various agricultural sectors, including row crops, vegetables, fruits, and ornamental plants. NewLeaf Symbiotics conducts extensive laboratory, greenhouse, and field trials to validate the effectiveness of its products, providing farmers with sustainable solutions to combat plant diseases and improve agricultural productivity. Originally founded as TrophoMax, LLC in 2011, the company rebranded in July 2012 to better reflect its mission and objectives in the agricultural biotechnology space.

FarmLead Resources Ltd. is a digital marketplace designed to enhance the buying and selling of grain, connecting farmers with verified buyers across North America. Founded in 2013 and based in Ottawa, Canada, the company operates in key agricultural regions including Alberta, Saskatchewan, Manitoba, and Ontario. Through its online platform and mobile application, FarmLead offers various services such as market research, grain testing, and price visibility, which help reduce brokerage fees and risks for farmers. The marketplace promotes efficiency, transparency, and equality within the grain industry, enabling farmers to negotiate better deals while allowing buyers to conveniently find the grain they need in their preferred locations.

BlueRock Therapeutics LP is a biotechnology company specializing in the development and manufacture of engineered cell therapies, focusing on neurology, cardiology, and immunology. Utilizing its CELL+GENE platform, the company aims to create induced pluripotent stem cell (iPSC) therapies to address a variety of diseases, with initial programs targeting heart muscle regeneration in patients who have experienced heart attacks or chronic heart failure. Founded in 2016 and headquartered in Cambridge, Massachusetts, BlueRock Therapeutics also maintains offices in New York and Toronto. The company provides stable master cell banks, including healthy donor cells and tools for immune evasion, facilitating the cultivation and expansion of these innovative therapies. As of late 2019, BlueRock Therapeutics operates as a subsidiary of Bayer Aktiengesellschaft.

Resson is a bioinformatics and data analytics company based in Fredericton, New Brunswick, specializing in customized agriculture solutions for large corporate clients. The company employs advanced technologies such as cloud-based data processing, swarm robotics, computer vision, and machine learning to enhance agricultural productivity. Its proprietary platform, the Resson Agricultural Management and Analytics System, analyzes crop metrics to assess the health and status of crops. By providing actionable insights derived from field data, Resson enables agricultural operators to optimize their operations, improve efficiency, increase yields, and maximize profitability.

Plant Response is a developer of agricultural technologies focused on enhancing plant health and growth through biological solutions. The company utilizes natural compounds to create products that improve plant immunity, increase tolerance to environmental stresses, and optimize nutrient use. By leveraging technology initially developed by researchers at the CBGP, Plant Response aims to address the challenges faced in modern agriculture and provide effective crop protection solutions. Their innovations are designed to meet the evolving needs of agricultural professionals globally, contributing to the restoration and advancement of the agricultural ecosystem.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on the agriculture industry through the development of biological products. Founded in 2012, AgBiome leverages its expertise in plant-associated microbes and modern genomics to create innovative solutions aimed at enhancing plant health, pest resistance, and crop yields. The company addresses critical agricultural challenges, including soil-borne diseases, insects, and nematodes, by offering fungicides and a platform that identifies and screens diverse microbial strains. AgBiome collaborates with prominent agricultural partners to accelerate discovery processes and broaden the reach of its sustainable products in global markets. With a dedicated team of over 85 employees and a state-of-the-art laboratory and greenhouse facility, AgBiome is committed to improving food production responsibly.